ABSTRACT
Objective While endothelial dysfunction has been implicated in the widespread thrombo-inflammatory complications of coronavirus disease-19 (COVID-19), the upstream mediators of endotheliopathy remain for the most part cryptic. Our aim was to identify circulating factors contributing to endothelial cell activation and dysfunction in COVID-19.
Methods Human endothelial cells were cultured in the presence of serum or plasma from 244 patients hospitalized with COVID-19 and plasma from 100 patients with non-COVID sepsis. Cell adhesion molecules (E-selectin, VCAM-1, and ICAM-1) were quantified by in-cell ELISA.
Results Serum and plasma from patients with COVID-19 increased surface expression of cell adhesion molecules. Furthermore, levels of soluble ICAM-1 and E-selectin were elevated in patient serum and tracked with disease severity. The presence of circulating antiphospholipid antibodies was a strong marker of the ability of COVID-19 serum to activate endothelium. Depletion of total IgG from antiphospholipid antibody-positive serum markedly restrained upregulation of cell adhesion molecules. Conversely, supplementation of control serum with patient IgG was sufficient to trigger endothelial activation.
Conclusion These data are the first to suggest that some patients with COVID-19 have potentially diverse antibodies that drive endotheliopathy, adding important context regarding thrombo-inflammatory effects of autoantibodies in severe COVID-19.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The work was supported by a grant from the Rheumatology Research Foundation to JSK and grants from the Michigan Medicine Frankel Cardiovascular Center and A. Alfred Taubman Medical Research Institute to YK and JSK. YZ was supported by a career development grant from the Rheumatology Research Foundation and a grant from the Arthritis National Research Foundation. JAM was partially supported by the VA Healthcare System. JSK was supported by grants from the NIH (R01HL115138), Burroughs Wellcome Fund, and Lupus Research Alliance. YK was supported by the Intramural Research Program of the NIH and NHLBI, Lasker Foundation, and the Falk Medical Research Trust Catalyst Award.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study complied with all relevant ethical regulations, and was approved by the University of Michigan Institutional Review Board (HUM00179409, HUM00131596, and HUM00044257).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵‡ Jason S. Knight and Yogendra Kanthi are co-corresponding authors
Competing interests: YK is an inventor on an unrelated pending patent to the University of Michigan (US20180369278A1). The remaining authors have no competing interests.
Contributors: HS, YZ, SN, AH, CKH, AAG, GS, SY, KG, JAM, JW, MZ, and YS conducted experiments and analyzed data. HS, YZ, MDM, JSK, and YK conceived the study and analyzed data. All authors participated in writing the manuscript and gave approval before submission.
Funding: The work was supported by a grant from the Rheumatology Research Foundation to JSK and grants from the Michigan Medicine Frankel Cardiovascular Center and A. Alfred Taubman Medical Research Institute to YK and JSK. YZ was supported by a career development grant from the Rheumatology Research Foundation and a grant from the Arthritis National Research Foundation. JAM was partially supported by the VA Healthcare System. JSK was supported by grants from the NIH (R01HL115138), Burroughs Wellcome Fund, and Lupus Research Alliance. YK was supported by the Intramural Research Program of the NIH and NHLBI, Lasker Foundation, and the Falk Medical Research Trust Catalyst Award.
Patient and public involvement: Patients and the public were not involved in design, conduct, reporting, or dissemination of this research.
Patient consent for publication: N/A
Ethics approval: This study complied with all relevant ethical regulations, and was approved by the University of Michigan Institutional Review Board (HUM00179409 and HUM00131596).
Data availability statement: All data relevant to the study are included in the article or uploaded as online supplemental information.
Data Availability
Upon publication in a peer-reviewed journal, data will be made available by the corresponding authors upon request.
